(News Bulletin 247) – Aelis Farma unveiled preclinical data on Monday showing the efficacy of AEF0217, its second drug candidate, in a mouse genetic model of autism spectrum disorder.
These results, presented at a European conference devoted to the Phelan-McDermid syndrome, showed the ability of AEF0217, in a mouse genetic model, to correct in a statistically significant way behavioral, cognitive and motor deficits, but also the alteration neurological, considered as one of the neurobiological markers of autism.
According to Aelis, these promising results open the way to analyze the feasibility of clinical development of AEF0217 in this indication and more generally in the field of autism spectrum disorder.
This compound is currently being evaluated as part of a phase 1/2 study in a first indication, the treatment of cognitive deficits in people with trisomy 21 (Down’s syndrome).
The title was up more than 3% on Monday on the Paris Stock Exchange following this announcement.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
